January - March 2006 in brief
* European Union granted BioTie 0.4 Million euros of research funding for the VAP-1 program * The net loss in January - March stood at EUR 2.3 million (in 2005 EUR -2.0 million). Cash flow from operating activities was EUR -2.2 million (EUR -2.5 million in 2005). * The company's liquid assets amounted to EUR 6.2 million as at March 31, 2006(at March 2005, EUR 5.5 million). The liquid resources are forecasted to be sufficient to finance the company's operations until the end of February 2007.
Biotie Therapies Corp.
Board of Directors
The full report including tables can be downloaded from the following link: